Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selective Response to Mammalian Target of Rapamycin Inhibition in a Patient with Metastatic Renal Cell Carcinoma Bearing TSC1 Mutation.

European urology - 1 Aug 2015

Ali Siraj M, Stephens Philip J, Miller Vincent A, Ross Jeffrey S, Pal Sumanta Kumar

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Renal Cell
Share to Drug Substitution
Share to Kidney Neoplasms
Share to Sirolimus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Tomography, X-Ray Computed

Share to TOR Serine-Threonine Kinases

Share to Tuberous Sclerosis Complex 1 Protein

Share to Tumor Suppressor Proteins

Source

Identifiers

PMID: 25796537
DOI: 10.1016/j.eururo.2015.03.002

Genes

TSC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selective Response to Mammalian Target of Rapamycin Inhibition in a Patient with Metastatic Renal Cell Carcinoma Bearing TSC1 Mutation.PMID 25796537Read ↗

Exceptional response to everolimus in a novel tuberous sclerosis complex-2 mutation-associated metastatic renal-cell carcinoma.Semantic proximity Read ↗

Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.Semantic proximity Read ↗

Unconventional mechanism of action and resistance to rapalogs in renal cancer.Semantic proximity Read ↗

Biallelic TSC2 Mutations in a Patient With Chromophobe Renal Cell Carcinoma Showing Extraordinary Response to Temsirolimus.Semantic proximity Read ↗

Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma.Semantic proximity Read ↗

Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.Semantic proximity Read ↗

TSC1 involvement in bladder cancer: diverse effects and therapeutic implicationsSemantic proximity Read ↗

Mammalian Target of Rapamycin Inhibitors Resistance Mechanisms in Clear Cell Renal Cell CarcinomaSemantic proximity Read ↗

PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinomaSemantic proximity Read ↗

Therapeutic approach guided by genetic alteration: use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expression.Semantic proximity Read ↗

Mutations in the PI3K/PTEN/TSC2 pathway contribute to mammalian target of rapamycin activity and increased translation under hypoxic conditions.Semantic proximity Read ↗

Enhancing mTOR-targeted cancer therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.